Web11 apr. 2024 · intel reports that on April 11, 2024, Morgan Stanley maintained coverage of Ionis Pharmaceuticals (NASDAQ:IONS) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 29.27% Upside... Web10 mei 2014 · View Archit Rastogi, PhD’S profile on LinkedIn, the world’s largest professional community. Archit has 8 jobs listed on their profile. …
Ionis Pharmaceuticals : 2024 Ionis Investor Day Presentation
Web29 jun. 2024 · Jun. 29, 2024, 07:00 AM BOSTON, June 29, 2024 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Tracy Palmer... Web11 feb. 2024 · CARLSBAD, Calif., Feb. 11, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that the European Medicines Agency (EMA) has granted orphan drug designation to ION373 for the treatment of people with Alexander disease, a severe, progressive and debilitating … therapeutic recreation month 2022
Ionis Pharmaceuticals : 2024 Ionis Investor Day Presentation
Web4 nov. 2024 · These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2024, and … WebIonis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness… WebAssistant Director. Ionis Pharmaceuticals, Inc. Nov 2024 - Present6 months. Carlsbad, California, United States. • Active support to the conduct of Tegpass and Cardiovascular … therapeutic recreation concordia